Correspondence 0001193125-24-216602 from Bicara Therapeutics Inc. (BCAX) (CIK 0002023658) (BCAX)
Bicara Therapeutics Inc. (BCAX) (CIK 0002023658)
Date: Sept. 10, 2024 · CIK: 0002023658 · Accession: 0001193125-24-216602
AI Filing Summary & Sentiment
File numbers found in text: 333-281722
Letter
September 10, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street NE
Washington, D.C. 20549
Attn: Tara Harkins, Vanessa Robertson, Daniel Crawford and Tim Buchmiller
Re: Bicara Therapeutics Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-281722)
Ladies and Gentleman:
In connection with the above-referenced Registration Statement, we wish to advise you that between September 6, 2024 and the date hereof, we effected the distribution of approximately 5,125 copies of the Company’s Preliminary Prospectus dated September 6, 2024 to prospective underwriters, institutional investors, dealers, brokers, individuals and others.
We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the Company that the effectiveness of the above-referenced Registration Statement be accelerated to 4:01 p.m. Eastern Time on September 12, 2024 or as soon thereafter as practicable.
[Remainder of page intentionally left blank]
Very truly yours,
MORGAN STANLEY & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 10, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street NE Washington, D.C. 20549 Attn: Tara Harkins, Vanessa Robertson, Daniel Crawford and Tim Buchmiller Re: Bicara Therapeutics Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-281722) Ladies and Gentleman: In connection with the above-referenced Registration Statement, we wish to advise you that between September 6, 2024 and the date hereof, we effected the distribution of approximately 5,125 copies of the Company’s Preliminary Prospectus dated September 6, 2024 to prospective underwriters, institutional investors, dealers, brokers, individuals and others. We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. We hereby join in the request of the Company that the effectiveness of the above-referenced Registration Statement be accelerated to 4:01 p.m. Eastern Time on September 12, 2024 or as soon thereafter as practicable. [Remainder of page intentionally left blank] Very truly yours, MORGAN STANLEY & CO. LLC TD SECURITIES (USA) LLC CANTOR FITZGERALD & CO. STIFEL, NICOLAUS & COMPANY, INCORPORATED As representatives of the several underwriters MORGAN STANLEY & CO. LLC By: /s/ Chris Rigoli Name: Chris Rigoli Title: Executive Director TD SECURITIES (USA) LLC By: /s/ Brian Hagerty Name: Brian Hagerty Title: Managing Director CANTOR FITZGERALD & CO. By: /s/ Asif Ahmed Name: Asif Ahmed Title: Co-Head of Equity Capital Markets, Managing Director STIFEL, NICOLAUS & COMPANY, INCORPORATED By: /s/ Ken Clausman Name: Ken Clausman Title: Managing Director [Signature Page to Request for Acceleration of Effectiveness]